Cargando…
Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
BACKGROUND: Current guidelines recommend vaccination against SARS-CoV2 for people with multiple sclerosis (pwMS). The long-term review of the safety and effectiveness of COVID-19 vaccines in pwMS is limited. METHODS: Service re-evaluation. PwMS using the MS service at Barts Health National Health Se...
Autores principales: | Allen-Philbey, K., Stennett, A., Begum, T., Johnson, A.C., MacDougall, A., Green, S., Dobson, R., Giovannoni, G., Gnanapavan, S., Marta, M., Smets, I., Turner, B.P., Baker, D., Mathews, J., Schmierer, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250705/ https://www.ncbi.nlm.nih.gov/pubmed/35816953 http://dx.doi.org/10.1016/j.msard.2022.104022 |
Ejemplares similares
-
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021) -
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023) -
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022) -
Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
por: Allen-Philbey, Kimberley, et al.
Publicado: (2020) -
Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)